TOKYO -- Japanese drugmaker Eisai will make its Alzheimer's disease treatment Leqembi available for at-home administration by fiscal 2025 in the U.S., where thousands of patients are waiting to ...

ALL RIGHT, WE HAVE THREE STATIONS TODAY. WE HAVE CHARADES, PICTIONARY AND CORNHOLE. 17 YEAR OLD ANDOVER HIGH SCHOOL JUNIOR JORDAN SHIRLEY IS A NATURAL BORN LEADER. SHE’S USING THOSE LEADERSHIP ...

ANDOVER, Kan. (KSNW) — Andover is rolling out their new $30,000 branding plan, logo included. The new logo was unveiled on the city’s Facebook page to controversy from some in Andover.

WICHITA, Kan. (KWCH) - Update: The City of Andover said Andover Fire-Rescue worked closely with a chemist from Sherwin-Williams to help extinguish the fire because it involved hazardous materials.

WICHITA, Kan. (KWCH) - UPDATE 4:10 A.M.: The Kansas Turnpike Authority confirms I-35 has reopened between Wichita and Andover. The Kansas Turnpike is closed between Wichita and Andover early ...

The constraint has been a lack of good drugs to treat those patients. Eisai and Biogen, with Leqembi, and Eli Lilly, with Kisunla, have begun the process of establishing a drug arsenal for ...

WICHITA, Kan. (KSNW) — First responders worked to extinguish a chemical fire in Andover early Friday. It started around 1 a.m. at the Sherwin-Williams manufacturing plant at one of the facility ...

On Monday, the FDA accepted Eisai Co., Ltd. (OTC:ESALY) and Biogen Inc’s (NASDAQ:BIIB) Biologics License Application (BLA) for lecanemab-irmb (Leqembi) subcutaneous autoinjector (SC-AI ...

Biogen (NASDAQ:BIIB) and Eisai (OTCPK:ESALF) (OTCPK:ESAIY) announced that the U.S. Food and Drug Administration (FDA) accepted a marketing application for an injectable version of their Alzheimer ...

FDA sets August 31, 2025, as the action date for Eisai and Biogen's Leqembi subcutaneous autoinjector application. Leqembi's subcutaneous dosing allows Alzheimer's patients to administer weekly ...

Eisai Co., Ltd. and Biogen Inc. have announced that the U.S. FDA has accepted Eisai's Biologics License Application for lecanemab-irmb, marketed as LEQEMBI, which is designed for subcutaneous ...

NEW YORK – The US Food and Drug Administration has accepted Eisai's biologics license application (BLA) seeking approval for a subcutaneous form of Leqembi (lecanemab) that can be dosed as maintenance ...